Imatinib has revolutionized drug therapy of chronic myeloid leukemia (CML). Preclinical
studies were promising but the results of clinical trials by far exceeded expectations …

Imatinib mesylate (Gleevec) was developed as the first molecularly targeted therapy that
specifically inhibits the BCR–ABL tyrosine kinase activity in patients with Philadelphia …

Background: Medullary and papillary thyroid carcinomas are often associated with
oncogenic activation of the RET tyrosine kinase. We evaluated whether the biaryl urea BAY …

To realize the full potential of targeted protein kinase inhibitors for the treatment of cancer, it
is important to address the emergence of drug resistance in treated patients. Mutant forms of …

Abstract Treatment of chronic myeloid leukemia (CML) with the tyrosine kinase inhibitor
imatinib represents a successful application of molecularly targeted cancer therapy. A rapid …

Abstract BMS-354825 (dasatinib) and AMN107 (nilotinib) are potent alternate Abl inhibitors
with activity against many imatinib mesylate–resistant BCR-ABL kinase domain (KD) …

Targeting the tyrosine kinase activity of Bcr-Abl is an attractive therapeutic strategy in chronic
myeloid leukemia (CML) and in Bcr-Abl–positive acute lymphoblastic leukemia. Whereas …

Overcoming imatinib mesylate (IM) resistance and disease persistence in patients with
chronic myeloid leukemia (CML) is of considerable importance to the issue of potential cure …

Imatinib is an effective therapy for chronic myeloid leukemia (CML), a myeloproliferative
disorder characterized by the expression of the recombinant oncoprotein Bcr-Abl. In this …

The Abl inhibitor imatinib is a highly effective therapy for patients with chronic myeloid
leukemia. Relapses are relatively uncommon in newly diagnosed patients, but are the rule …